Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?

Autor:	Matthew, Roe, Courtenay Gilmore, Wilson, Carriedelle Wilson, Fusco, Stephen, Hulkower, Sue, Stigleman
Rok vydání:	2020
Předmět:	Adult Aged 80 and over Male Norway Narcotic Antagonists Administration Sublingual Middle Aged Opioid-Related Disorders Injections Intramuscular United States Delayed-Action Preparations Humans Female Buprenorphine Naloxone Drug Combination Aged
Zdroj:	The Journal of family practice. 69(10)
ISSN:	1533-7294
Popis:	YES. MONTHLY EXTENDED-RELEASE INJECTABLE NALTREXONE (XR-NTX) TREATS OPIOID USE DISORDER AS EFFECTIVELY AS DAILY SUBLINGUAL BUPRENORPHINE-NALOXONE (BUP-NX) WITHOUT CAUSING ANY INCREASE IN SERIOUS ADVERSE EVENTS OR FATAL OVERDOSES. (STRENGTH OF RECOMMENDATION: A, 2 GOOD-QUALITY RCTS).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::8d2e2c9454c7b6318bf5fb0a4aa66288 https://pubmed.ncbi.nlm.nih.gov/33348352 Zobrazit plný text záznamu Plný text ve formátu PDF